This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Firocoxib 57 mg|
|Indication||Relief of pain and control of inflammation associated with osteoarthritis and other musculoskeletal disorders. Control of postoperative pain associated with surgery; including soft tissue, orthopaedic and dental procedures.|
|Contraindications||Administration to cats, as a dose level for firocoxib has not been established in this species. Administration to any dog that has previously exhibited hypersensitivity to firocoxib.|
|Actions||Firocoxib is a nonsteroidal anti-inflammatory compound with anti-inflammatory, analgesic and antipyretic activity. Firocoxib, specifically developed for use in veterinary medicine, is a highly selective inhibitor of the inducible isoform COX-2 and is a member of the coxib class. In vitro canine whole blood assays have demonstrated firocoxib to be 350 to 430 times more selective for COX-2 than COX-1. Dog plasma drug levels following treatment at therapeutic levels compared with inhibitory concentration curves from in vitro canine whole blood assays indicate there is no inhibition of COX-1.|
|Precautions||As a therapeutic class, cyclooxygenase inhibiting anti-inflammatory drugs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug associated events varies between patients. The possibility of predisposing conditions with the potential for renal disease (e.g. cardiac or vascular disease, and advanced age) or gastrointestinal bleeding (e.g. prolonged bleeding time and gastrointestinal disease) should be considered before commencing therapy. Hepatic disease may reduce drug metabolism. Pretreatment assessment and regular follow up monitoring is required for patients at risk of such conditions.Hypovolaemia or hypotension (e.g. during anaesthesia) should be corrected prior to use.Safe use in breeding, pregnant or lactating dogs, or in puppies less than 10 weeks of age, has not been established.Prior to administration of any NSAIDS it is advisable to conduct a physical examination and appropriate laboratory tests to establish pretreatment parameters.In long term use, dogs should be evaluated periodically to make sure the drug is still necessary and well tolerated.Harmful if swallowed. Wash hands after use.First Aid If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.Disposal Wrap empty packaging or unused product with paper and place in garbage.|
|Dosage and Administration||The recommended dose of Previcox in dogs is 5 mg/kg bodyweight once daily. Daily therapy should be given for the expected duration of pain and inflammation, based on the nature of the condition being treated. For prolonged therapy of chronic conditions, patients should be monitored regularly for possible drug related side effects (see Precautions). Tablets are scored, and dose should be measured using half tablets where needed. May be administered with or without food.|
|Storage||Store below 30°C (room temperature).|
|MSDS (external link)||Previcox Tablets 57mg (60) MSDS|
|Label (external link)||Previcox Tablets 57mg (60) Label|
|Manufacturer||Boehringer Ingelheim Animal Health Australia Pty Ltd|